Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
16
pubmed:dateCreated
2004-9-24
pubmed:abstractText
With the increasing incidence and mortality of cancer worldwide, there is an urgent need for new therapeutic approaches. Gene therapy is one such approach and preliminary data are promising. Viral and nonviral vector systems for gene delivery are available, but most of the current systems suffer from disadvantages such as low transfection efficiencies, in vivo instability, targeting problems, mutagenic potential and immunogenicity. Viruses of the Parvoviridae family, which are characterised by their oncotropism, oncosuppression, long-term gene expression and human apathogenicity, potentially offer advantages as viral vectors. This article evaluates their usefulness in gene therapy strategies for cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1462-3994
pubmed:author
pubmed:issnType
Electronic
pubmed:day
23
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-24
pubmed:meshHeading
pubmed-meshheading:15387896-Angiogenesis Inhibitors, pubmed-meshheading:15387896-Cancer Vaccines, pubmed-meshheading:15387896-Dependovirus, pubmed-meshheading:15387896-Gene Targeting, pubmed-meshheading:15387896-Gene Therapy, pubmed-meshheading:15387896-Genes, Transgenic, Suicide, pubmed-meshheading:15387896-Genetic Vectors, pubmed-meshheading:15387896-Genome, Viral, pubmed-meshheading:15387896-Hematopoietic Stem Cells, pubmed-meshheading:15387896-Humans, pubmed-meshheading:15387896-Models, Biological, pubmed-meshheading:15387896-Neoplasms, pubmed-meshheading:15387896-Organ Specificity, pubmed-meshheading:15387896-Parvovirus, pubmed-meshheading:15387896-Suppression, Genetic, pubmed-meshheading:15387896-Vaccines, Synthetic, pubmed-meshheading:15387896-Viral Proteins, pubmed-meshheading:15387896-Virus Replication
pubmed:year
2004
pubmed:articleTitle
Parvovirus vectors: use and optimisation in cancer gene therapy.
pubmed:affiliation
Molecular Medicine Program, Mayo Clinic, 200 First Street SW, Guggenheim 18-33, Rochester, MN 55905, USA. blechacz.boris@mayo.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Evaluation Studies